The biotechnology company has validated in seven European markets a patent based on plant cell cultures with rejuvenating and healing applications on skin cells. The protection will remain until 2036 and reinforces Vytrus' strategy in one of the main global markets for cosmetic ingredients.
Plant biotechnology continues to gain weight as a source of innovation for the cosmetic industry. Vytrus Biotech has extended the international protection of one of its technologies after validating in seven European countries a patent related to skin rejuvenation and healing.
The patent, granted by the European Patent Office (EPO) on April 29, has now been validated in Germany, United Kingdom, France, Italy, Poland, Spain, and Switzerland. The protection will be valid in these markets until April 11, 2036. The technology is covered under the title Cell-Free Plant Cell Culture Suspension Supernatant with Re-Youth and/or Wound Healing Activity Over Skin Cells and protects the use of supernatants from plant cell cultures for applications related to rejuvenating and healing activity on skin cells.
The company, born in Terrassa as a spin-off linked to the University of Barcelona, focuses part of its technological platform on plant cell culture and on obtaining active ingredients for different cosmetic needs. It currently has ingredients on the market and a commercial network that extends through Europe, Asia-Pacific, the Middle East, and America.
Vytrus has already obtained other international protections linked to both skin care and the treatment and prevention of hair loss. In May 2025, for example, the company obtained a patent in the United States related to healing applications of its portfolio and with ingredients rich in plant peptides and natural plant exosomes.
Europe, strategic market
The validation of the patent also has a relevant commercial dimension. Europe, including Spain, represented 70% of Vytrus' sales during 2025, according to data communicated by the company. The protection of the technology in seven markets thus reinforces its positioning in a region especially relevant for the cosmetic ingredients business.
Vytrus' international strategy is based on a portfolio of protected technologies and the expansion of its ingredients into different markets. The company closed 2024 with commercial presence in 39 countries across five continents, while its ingredients for anti-aging, hair care, sun protection, and sensitive skin applications were among the main drivers of sales growth.
Intellectual property gains weight in cosmetic innovation
Beyond the patent itself, the move reflects a relevant trend for the sector: intellectual property is becoming a strategic asset for cosmetic ingredient suppliers, especially in areas such as biotechnology, peptides, exosomes, and cell culture technologies.
Protecting a technological platform in key markets not only allows for defending an innovation against potential competitors but also increases the differential value of the ingredients developed from it.
For Vytrus, the European validation also consolidates a technology that combines two areas of growing interest for the industry: the search for cellular rejuvenation mechanisms and the development of plant-based biotechnological ingredients. The company thus continues to build an intellectual property portfolio aimed at transforming biotechnological research into new opportunities for the cosmetic market.